Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 5
2009 5
2010 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).
Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP; MRC RT01 collaborators. Syndikus I, et al. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):773-83. doi: 10.1016/j.ijrobp.2009.05.052. Epub 2009 Oct 14. Int J Radiat Oncol Biol Phys. 2010. PMID: 19836155 Free PMC article. Clinical Trial.
METHODS AND MATERIALS: The UK Medical Research Council RT01 trial included 843 men with localized prostate cancer, who were treated for 6 months with neoadjuvant radiotherapy and were randomly assigned to either 64-Gy or 74-Gy CFRT. Toxicity was evaluated before CFRT and during l …
METHODS AND MATERIALS: The UK Medical Research Council RT01 trial included 843 men with localized prostate cancer, who were treated for 6 mo …
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.
Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Dearnaley DP, et al. Lancet Oncol. 2009 Sep;10(9):872-6. doi: 10.1016/S1470-2045(09)70201-3. Epub 2009 Aug 10. Lancet Oncol. 2009. PMID: 19674936 Free PMC article.
The Medical Research Council (MRC) PR05 and PR04 randomised controlled trials assessed the use of sodium clodronate, an oral, first-generation bisphosphonate. We report the final analyses of long-term survival data with additional follow-up in both trials. METHODS: 311 men …
The Medical Research Council (MRC) PR05 and PR04 randomised controlled trials assessed the use of sodium clodronate, an oral, first-generati …
A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies.
Attard G, Rizzo S, Ledaki I, Clark J, Reid AH, Thompson A, Khoo V, de Bono JS, Cooper CS, Hudson DL. Attard G, et al. Prostate. 2009 Oct 1;69(14):1507-20. doi: 10.1002/pros.20997. Prostate. 2009. PMID: 19544327
Gains and losses previously described in clinical prostate tumors, most notably loss of 8(p) and gain of 8(q), were identified on comparative genomic hybridization and long-term growth in culture, survival in methylcellulose and invasion through matrigel confirmed the mali …
Gains and losses previously described in clinical prostate tumors, most notably loss of 8(p) and gain of 8(q), were identified on comparativ …
p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.
Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham J, Møller H, Kattan MW, Cooper CS, Scardino P, Cuzick J, Berney DM. Kudahetti S, et al. BJU Int. 2009 Jul;104(1):20-4. doi: 10.1111/j.1464-410X.2009.08407.x. Epub 2009 Feb 23. BJU Int. 2009. PMID: 19239456
OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS AND METHODS We examined p53 expression by immunoh …
OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of c …
Active surveillance with selective radical treatment for localized prostate cancer.
van As NJ, Parker CC. van As NJ, et al. Cancer J. 2007 Sep-Oct;13(5):289-94. doi: 10.1097/PPO.0b013e318156ff65. Cancer J. 2007. PMID: 17921727 Review.
Active surveillance with selective radial intervention is a management strategy that offers patients the hope of avoiding "unnecessary" treatment without detriment to their long-term survival. Here we discuss the rationale for active surveillance, and the early results. .. …
Active surveillance with selective radial intervention is a management strategy that offers patients the hope of avoiding "unnecessary" trea …
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.
Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Haluska P, et al. Clin Cancer Res. 2007 Oct 1;13(19):5834-40. doi: 10.1158/1078-0432.CCR-07-1118. Clin Cancer Res. 2007. PMID: 17908976 Clinical Trial.
At 20 mg/kg, 10 of 15 patients experienced stability of disease. Two of these patients experienced long-term stability. There were no objective responses. Pharmacokinetic analysis revealed a dose-dependent increase in CP-751,871 exposure and approximately 2-fold accumulati …
At 20 mg/kg, 10 of 15 patients experienced stability of disease. Two of these patients experienced long-term stability. There were no …
Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer.
Murthy V, Norman AR, Barbachano Y, Parker CC, Dearnaley DP. Murthy V, et al. BJU Int. 2007 Jun;99(6):1380-2. doi: 10.1111/j.1464-410X.2007.06843.x. BJU Int. 2007. PMID: 17537213
OBJECTIVE: To assess whether a long-term follow-up shows any reduction in the level of luteinizing hormone (LH) secretion, which could result in declining testosterone levels in men with localized prostate cancer, as most (96%) men have testosterone levels within the norma …
OBJECTIVE: To assess whether a long-term follow-up shows any reduction in the level of luteinizing hormone (LH) secretion, which coul …
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK; RT01 collaborators. Dearnaley DP, et al. Lancet Oncol. 2007 Jun;8(6):475-87. doi: 10.1016/S1470-2045(07)70143-2. Lancet Oncol. 2007. PMID: 17482880 Clinical Trial.
BACKGROUND: In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term efficacy, potentially at the cost of increased toxi …
BACKGROUND: In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard- …
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397).
Dearnaley DP, Sydes MR, Langley RE, Graham JD, Huddart RA, Syndikus I, Matthews JH, Scrase CD, Jose CC, Logue J, Stephens RJ; RT01 Collaborators. Dearnaley DP, et al. Radiother Oncol. 2007 Apr;83(1):31-41. doi: 10.1016/j.radonc.2007.02.014. Epub 2007 Mar 27. Radiother Oncol. 2007. PMID: 17391791 Clinical Trial.
Conformal radiotherapy (CFRT) raises the possibility that radiotherapy doses can be increased and long-term efficacy outcomes improved, with safety an important consideration. ...
Conformal radiotherapy (CFRT) raises the possibility that radiotherapy doses can be increased and long-term efficacy outcomes improve …
12 results